Jump Financial LLC Purchases Shares of 13,494 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Jump Financial LLC purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 4th quarter, Holdings Channel.com reports. The fund purchased 13,494 shares of the company’s stock, valued at approximately $91,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after purchasing an additional 9,737,196 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Recursion Pharmaceuticals by 12.1% during the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company’s stock valued at $41,160,000 after buying an additional 655,238 shares in the last quarter. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $23,429,000. Charles Schwab Investment Management Inc. raised its position in Recursion Pharmaceuticals by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,274,003 shares of the company’s stock worth $15,372,000 after purchasing an additional 333,323 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Recursion Pharmaceuticals by 6.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock worth $7,751,000 after purchasing an additional 67,464 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX opened at $5.84 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm’s 50 day moving average price is $6.11 and its 200-day moving average price is $6.78. Recursion Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a market cap of $2.35 billion, a PE ratio of -3.82 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the business posted ($0.42) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% on a year-over-year basis. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on RXRX. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Morgan Stanley dropped their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 10th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.20.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.